Airlines

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier? (Bombardier Stock Quote, Chart, News, Analysts, Financials TSX:BBD.B).

Yes, says Desjardins Securities analyst Benoit Poirier who May 2 maintained his “Buy” rating and raised his price target on BBD.B from $101.00 to $102.00.

As reported by The Globe and Mail, the analyst attended the company’s annual investor May 1 and came away impressed.

“BBD reaffirmed its 2025 targets, noting that it is well on track to meet its objectives, and provided additional details on how it plans to achieve them,” Poirier wrote. “This should provide investors with confidence that the US$900-million FCF target is achievable—consensus (US$854-million) is currently below this threshold. BBD also introduced new long-term 2030 growth target, but most importantly, (1) they can all be achieved organically with internal resources and limited capex; and (2) are incremental and do no count on any increase in deliveries as management indicated that the 150 aircraft/year will be the new cruising altitude. We view this as positive as BBD has in the past (previous management team) over-delivered and chased volume/sales to fund its civil investments (and investors have long memories). BBD is a much different company today with a different business plan; back in 2008–09, BBD had a significant percentage of its backlog exposed to bizjet resellers/agents/speculators with unfavourable payment terms (cancelled orders when the Great Financial Crisis hit), in addition to having exposure to the more elastic light jet market with the Learjet. Since then, BBD has cancelled all of those reseller agreements and now uses an internal sales team (no exposure in current backlog) and no longer manufactures any light jets (discontinued Learjet in 2022).”

The analyst broke down the numbers he expects to see from Bombardier.

“Assuming a 22-per-cent EBITDA margin in 2030, which we believe is a fair estimate given the greater mix weighting to aftermarket, defence and pre-owned (all three of these businesses generate accretive 20-per-cent-plus EBITDA margins) and given BBD’s previous 2025 EBITDA margin target was 20 per cent (an additional 200 basis points of expansion over five years does not seem like that far of a stretch), we calculate a potential EBITDA contribution of US$2.860-billion in 2030,” Poirier said. “Stripping out the capex target of US$300-million as well as a fair assumption for cash interest and working capital investment, we derive potential FCF of US$1.960-billion in 2030. This implies a 16.8% CAGR [compound annual growth rate] vs the 2025 target of US$900-million, and total potential FCF of US$7.353-billlion from 2026–30. This amount of cash can be applied to various endeavours as we explore in the paragraph below. To conclude, placing our current valuation exit multiple of 8.6 times on our 2030 EBITDA assumption, and making some conservative assumptions for leverage and share buybacks, we calculate a potential target price of C$326, which implies a seven-year CAGR vs yesterday’s close of 25.2 per cent.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: bbd.b
Staff

Recent Posts

EGLX has price target slashed at Haywood

Following the company's first quarter results, Haywood analyst Gianluca Tucci has cut his price target on Enthusiast Gaming (Enthusiast Gaming… [Read More]

11 hours ago

Is Dexterra Group a buy?

Its first quarter results are in the books and Beacon analyst Kirk Wilson has lowered his price target on Dexterra… [Read More]

23 hours ago

Is AYR stock a buy?

Following the company's first quarter results, Beacon analyst Russell Stanley has maintained his "Buy" rating on Ayr Wellness (Ayr Wellness… [Read More]

1 day ago

Cresco Labs earns target raise at Echelon

Following the company's first quarter results, Echelon Capital Markets analyst Andrew Semple has raised his price target on Cresco Labs… [Read More]

1 day ago

SSTI is a buy, Roth says

Its first quarter results are in the book and Roth MKM analyst Richard K Baldry is still bullish on SoundThinking… [Read More]

2 days ago

GLXY wins price target raise at ATB Capital

Following the company's first quarter results, ATB Capital Markets analyst Martin Toner has raised his price target on Galaxy Digital… [Read More]

2 days ago